After a @-week run-in period ( gemcitabine @ mg m ( -@ ) once weekly plus erlotinib @ mg per day ) , patients with metastatic pancreatic cancer who developed grade @/@ rash were randomised to receive gemcitabine plus erlotinib dose escalation ( @ mg , increasing by @ mg every @ weeks ( maximum @ mg ) ; n = @ ) or gemcitabine plus standard-dose erlotinib ( @ mg per day ; n = @ ) .